These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
631 related articles for article (PubMed ID: 6604610)
21. C3 metabolism in a patient with deficiency of the second component of complement (C2) and discoid lupus erythematosus. Wild JH; Zvaifler NJ; Müller-Eberhard HJ; Wilson CB Clin Exp Immunol; 1976 May; 24(2):238-48. PubMed ID: 1084239 [TBL] [Abstract][Full Text] [Related]
23. Generation of the classical pathway C3 convertase (EAC4b2a) by proteolytic enzymes. Loos M; Heinz HP Acta Pathol Microbiol Immunol Scand Suppl; 1984; 284():67-74. PubMed ID: 6375257 [TBL] [Abstract][Full Text] [Related]
24. Role of the C3b-binding site on C4b-binding protein in regulating classical pathway C5 convertase. Rawal N; Pangburn MK Mol Immunol; 2007 Feb; 44(6):1105-14. PubMed ID: 16979240 [TBL] [Abstract][Full Text] [Related]
25. Modulation of the activity of the classical complement pathway C3 convertase by surface-bound C3 or C5. Strunk RC; Giclas PC J Immunol; 1980 Feb; 124(2):520-6. PubMed ID: 7356706 [No Abstract] [Full Text] [Related]
26. Isolation of C4-binding protein from guinea pig plasma and demonstration of its function as a control protein of the classical complement pathway C3 convertase. Burge J; Nicholson-Weller A; Austen KF J Immunol; 1981 Jan; 126(1):232-5. PubMed ID: 6778916 [TBL] [Abstract][Full Text] [Related]
27. Heterogeneity, polypeptide chain composition and antigenic reactivity of autoantibodies (F-42) that are directed against the classical pathway C3 convertase of complement and isolated from sera of patients with systemic lupus erythematosus. Daha MR; Hazevoet HM; van Es LA Clin Exp Immunol; 1984 Jun; 56(3):614-20. PubMed ID: 6430610 [TBL] [Abstract][Full Text] [Related]
28. Prevention of immune precipitation by purified classical pathway complement components. Naama JK; Hamilton AO; Yeung-Laiwah AC; Whaley K Clin Exp Immunol; 1984 Nov; 58(2):486-92. PubMed ID: 6333948 [TBL] [Abstract][Full Text] [Related]
29. Interaction between serum amyloid P component and C4b-binding protein associated with inhibition of factor I-mediated C4b degradation. García de Frutos P; Dahlbäck B J Immunol; 1994 Mar; 152(5):2430-7. PubMed ID: 8133054 [TBL] [Abstract][Full Text] [Related]
30. Evaluation of alternative pathway and factor B haemolytic activities in patients with systemic lupus erythematosus: correlations with the alternative pathway regulatory proteins. Aguado MT; Perrin LH; Ramirez R; Miescher PA; Lambert PH Clin Exp Immunol; 1980 Dec; 42(3):495-505. PubMed ID: 6163579 [TBL] [Abstract][Full Text] [Related]
31. Complement inhibitor C4b-binding protein in primary Sjögren's syndrome and its association with other disease markers. Zadura AF; Theander E; Blom AM; Trouw LA Scand J Immunol; 2009 Apr; 69(4):374-80. PubMed ID: 19284503 [TBL] [Abstract][Full Text] [Related]
32. [Lupus and protein deficiencies of the classical complement pathway]. Weiss L; Maillet F; Kazatchkine M Rev Prat; 1990 Sep; 40(21):1937-40. PubMed ID: 2237185 [TBL] [Abstract][Full Text] [Related]
33. Studies on the haemolytic activity of circulating C1q-C3/C4 complexes. Wouters D; Brouwer MC; Daha MR; Hack CE Mol Immunol; 2008 Apr; 45(7):1893-9. PubMed ID: 18054386 [TBL] [Abstract][Full Text] [Related]
34. Evaluation of classical complement pathway activation in rheumatoid arthritis: measurement of C1q-C4 complexes as novel activation products. Wouters D; Voskuyl AE; Molenaar ET; Dijkmans BA; Hack CE Arthritis Rheum; 2006 Apr; 54(4):1143-50. PubMed ID: 16572449 [TBL] [Abstract][Full Text] [Related]
35. Complement component C2, inhibiting a latent serine protease in the classical pathway of complement activation. Halili MA; Ruiz-Gómez G; Le GT; Abbenante G; Fairlie DP Biochemistry; 2009 Sep; 48(35):8466-72. PubMed ID: 19642650 [TBL] [Abstract][Full Text] [Related]
36. [Consumption hypocomplementemia: comparative value of haemolytic and protein estimations of the components of the classical pathway (author's transl)]. Roncato M; Vial MC; Maillet F; Peltier A Nouv Presse Med; 1979 May; 8(20):1657-60. PubMed ID: 112575 [TBL] [Abstract][Full Text] [Related]
37. A complement-resistant HeLa cell line (T638) is blocked at the step of C3 deposition. Santi P; Joiner KA; Hammer CH; Frank MM; Tosi R J Immunol; 1987 May; 138(10):3385-91. PubMed ID: 2952716 [TBL] [Abstract][Full Text] [Related]
38. Reduced uptake of apoptotic cells by macrophages in systemic lupus erythematosus: correlates with decreased serum levels of complement. Bijl M; Reefman E; Horst G; Limburg PC; Kallenberg CG Ann Rheum Dis; 2006 Jan; 65(1):57-63. PubMed ID: 15919679 [TBL] [Abstract][Full Text] [Related]
39. A longitudinal study of circulating immune complexes, dna antibodies and complement in patients with systemic lupus erythematosus: an analysis of their relationship to disease activity. Harkiss GD; Hazleman BL; Brown DL J Clin Lab Immunol; 1979 Nov; 2(4):275-83. PubMed ID: 537024 [TBL] [Abstract][Full Text] [Related]
40. [Complement components, whole complement activity, and circulating immune complexes in neoplastic diseases]. Takada K; Morishita M; Sugiura T; Suzuki M; Torii Y; Ichimura K; Hashigami H; Toshikawa K; Ina Y; Yamamoto M; Oyama A; Urata A Gan No Rinsho; 1983 Apr; 29(4):A-19, 293-6. PubMed ID: 6602233 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]